Key takeaways

• Two pathways, one axis: CJC-1295 acts on the GHRH receptor; Ipamorelin acts on the ghrelin receptor (GHS-R1a).
• Produce + release: one signal drives GH synthesis, the other drives its secretion — they stack additively in models.
• Selectivity: Ipamorelin keeps the pulse “clean,” with minimal cortisol or prolactin involvement.
• Physiological feedback: the stack stimulates endogenous GH rather than bypassing it, preserving regulatory feedback in research systems.
• Why it’s studied: combination models report larger GH elevations than either compound alone.
• Format: both are supplied as lyophilized powders with batch-specific third-party analytics.

What is the CJC-1295 + Ipamorelin stack?

The stack is a research pairing of two distinct growth-hormone secretagogues that are studied together because their mechanisms overlap in effect but not in pathway. Each component plays a defined role:

• CJC-1295 (No-DAC / Modified GRF 1-29) — a synthetic GHRH analog engineered to resist enzymatic degradation while preserving high-affinity binding at the GHRH receptor. It mimics the body’s own “produce more GH” signal.
• Ipamorelin — a selective pentapeptide that binds the ghrelin receptor (GHS-R1a) and triggers GH release without significantly raising cortisol, prolactin, or appetite signaling.

NeuroPept Labs supplies both as research-grade lyophilized peptides verified through independent analytical testing. For a deeper look at the No-DAC form specifically, see our companion guide on CJC-1295 No-DAC vs DAC. A broader index of the published literature on this GHRH analog is available through the PubMed database.

Mechanism: two complementary signals

The reason this combination is studied so often comes down to receptor biology. The two compounds engage different cell-surface receptors on pituitary somatotrophs and converge on the same outcome — a GH pulse — through separate signaling routes:

• CJC-1295 → GHRH receptor. Activation raises intracellular cyclic AMP (cAMP), promoting GH synthesis and priming the somatotroph to release more hormone.
• Ipamorelin → ghrelin receptor (GHS-R1a). Activation drives phospholipase C signaling, inositol trisphosphate generation, and calcium mobilization, triggering release of stored GH.

When both receptors are engaged at once, the “produce” signal and the “release” signal reinforce each other. In published research models, the combination consistently elevates GH more than either compound on its own, which is the central observation motivating combination studies. Crucially, because Ipamorelin is selective, the amplified pulse is not accompanied by the cortisol and prolactin elevations seen with older, less selective growth hormone-releasing peptides.

Why the combination is studied: synergy in models

Researchers are interested in the stack because it produces a layered effect that single-pathway stimulation cannot replicate. The contrast is clearest when the approaches are placed side by side:

Several properties make this pairing attractive as a research tool:

• Additive pathways — two receptors, two signaling cascades, one reinforced output.
• Cleaner data — Ipamorelin’s selectivity limits confounding cortisol/prolactin shifts.
• Extended window — CJC-1295’s longer functional duration overlaps Ipamorelin’s rapid pulse.
• Comparability — a well-characterized stack serves as a benchmark for newer secretagogues.

Kinetic profiles: why timing matters

Part of what makes the pairing informative is that the two compounds operate on different timescales, so their effects overlap rather than simply adding at a single instant:

• CJC-1295 No-DAC — produces a sustained signal that mimics the body’s pulsatile GHRH pattern, with a longer functional duration than a ghrelin agonist’s pulse.
• Ipamorelin — produces a rapid-onset, short-lived release event rather than a prolonged elevation.
• Overlap — when administered together in a model, the extended “produce” window coincides with the sharp “release” event, widening the combined signaling window.
• Design implication — sampling intervals and the ratio between the two peptides are chosen around these differing kinetics so that the synergy can be measured cleanly.

This timescale difference is also why the stack is often contrasted with single-compound protocols: the combined kinetic profile is something neither peptide reproduces on its own.

Physiological feedback and research applications

A distinguishing feature of this stack in research is that it stimulates the body’s own GH machinery rather than replacing it. Because the somatotroph still controls the final release, models that use the combination retain native feedback loops — an important difference from approaches that introduce exogenous GH directly. This makes the pairing useful across several documented research directions:

• Neuroendocrinology — modeling hypothalamic-pituitary-somatotropic axis regulation under dual stimulation.
• Metabolic research — examining GH- and IGF-1-mediated signaling in glucose handling and lipolysis.
• Receptor pharmacology — characterizing how GHRH-receptor and GHS-R1a activation interact.
• Comparative studies — benchmarking combined versus single-pathway stimulation.

Within these areas, the endpoints researchers most often track help explain why a clean, reproducible pulse is so valuable:

• GH pulse amplitude — the peak height of the combined release compared with single-compound controls.
• IGF-1 dynamics — downstream signaling as a marker of sustained GH activity.
• Off-target hormones — cortisol and prolactin, monitored to confirm selectivity is preserved.
• Pulse duration — how long the combined signaling window remains elevated.

The selectivity that makes Ipamorelin valuable here was first established when it was introduced as the first selective growth hormone secretagogue, a property that still underpins its role in modern combination research.

Handling, reconstitution, and quality verification

Both peptides are supplied as lyophilized (freeze-dried) powders for stability. Because the integrity of each compound affects the validity of any combination study, careful handling is essential:

• Storage (unreconstituted) — keep both lyophilized vials cold and protected from light until use.
• Reconstitution — add diluent slowly down the vial wall and swirl gently rather than shaking.
• Separate preparation — reconstitute and characterize each peptide individually so concentrations are known precisely.
• Documentation — confirm a batch-specific certificate of analysis (COA) accompanies each compound.

Every NeuroPept Labs batch is synthesized under controlled conditions and accompanied by a COA. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code found in the product images. For background on the analytics behind those documents, see our research-grade quality guide covering HPLC and mass spectrometry.

Considerations for experimental design

Because the value of the stack lies in a clean, amplified GH pulse, study design has an outsized effect on data quality. Researchers working with the combination commonly account for several variables:

• Pulse timing — sampling windows are aligned to the expected combined peak rather than measured at arbitrary intervals.
• Relative concentrations — the ratio of the two peptides is standardized across runs so synergy can be attributed rather than assumed.
• Receptor desensitization — repeated GHRH-receptor and GHS-R1a stimulation can blunt responses, so washout intervals are controlled.
• Baseline endocrine state — cortisol, prolactin, and IGF-1 baselines are characterized so selective effects can be isolated.
• Model selection — somatotroph responsiveness differs across cell lines and animal models, affecting comparability.

These controls underscore why verified, high-purity starting material matters: batch-to-batch inconsistency in either peptide would undermine every downstream comparison the stack is designed to support.

Frequently asked questions

What does the CJC-1295 and Ipamorelin stack do in research?

In research models the combination stimulates a larger growth hormone pulse than either peptide alone by engaging two separate receptors — CJC-1295 on the GHRH receptor and Ipamorelin on the ghrelin receptor. It is studied as a tool for examining somatotropic-axis signaling and is intended for in vitro and laboratory research only.

Why are CJC-1295 and Ipamorelin used together?

They act on different receptors with complementary effects: CJC-1295 signals the pituitary to produce growth hormone, while Ipamorelin signals it to release stored growth hormone. Combining the “produce” and “release” signals reinforces the overall response in research models.

Does the stack raise cortisol or prolactin?

One reason this pairing is favored in research is that Ipamorelin is selective, so the amplified growth hormone pulse is generally not accompanied by the cortisol and prolactin elevations associated with older, less selective growth hormone-releasing peptides.

How is CJC-1295 No-DAC different from the DAC form?

CJC-1295 No-DAC lacks the albumin-binding Drug Affinity Complex, giving it a shorter, more pulsatile profile that mimics endogenous secretion, whereas the DAC form has a much longer duration. See our dedicated CJC-1295 No-DAC vs DAC guide for a full comparison.

What form do these peptides come in?

Both are supplied as lyophilized (freeze-dried) powders that are reconstituted before laboratory use and stored under refrigeration. Research-grade material should always be accompanied by a batch-specific certificate of analysis from an independent laboratory.

Is the CJC-1295 and Ipamorelin stack approved for human use?

No. These compounds offered for research are intended strictly for in vitro and laboratory investigation and are not approved for human consumption or clinical use. All information here is educational and not medical advice.